Enovis Corporation Reports Q2 2025 Financial Results

Enovis Corporation ( (ENOV) ) has released its Q2 earnings. Here is a breakdown of the information Enovis Corporation presented to its investors.

Enovis Corporation is an innovation-driven medical technology growth company, focusing on developing clinically differentiated solutions to improve patient outcomes in the orthopedics sector. The company is known for its commitment to continuous improvement and innovation, with a diverse portfolio of products and services that support active lifestyles.

In its second quarter of 2025, Enovis Corporation reported a 7% increase in net sales, reaching $565 million, driven by strong performance in its Reconstructive segment, which saw an 11% growth year-over-year. Despite this growth, the company reported a net loss of $37 million, equating to a loss of 6.5% of sales, while achieving an adjusted EBITDA of $97 million, or 17.2% of sales.

Key financial highlights include the robust growth in the Reconstructive segment, which increased by 11% on a reported basis and 8% on an organic basis. The Prevention and Recovery segment also contributed with a 5% growth on a reported basis. The company’s adjusted net earnings per diluted share were $0.79, reflecting its strategic focus on scalable and capital-efficient execution.

Looking ahead, Enovis has updated its financial expectations for 2025, projecting revenues between $2.245 billion and $2.275 billion, and adjusted EBITDA between $392 million and $402 million. The company remains optimistic about its growth potential, emphasizing operational discipline and a focus on unlocking the full value of its orthopedic platform.

Enovis Corporation’s management is confident in its strategic direction and remains committed to enhancing shareholder value while continuing to help millions lead active lives through its innovative medical technology solutions.